Protara Therapeutics (NASDAQ:TARA) Stock Price Up 0.8% – Still a Buy?

Protara Therapeutics, Inc. (NASDAQ:TARA)’s stock price rose 0.8% during trading on Tuesday . The company traded as high as $2.74 and last traded at $2.61. Approximately 262,497 shares changed hands during trading, an increase of 20% from the average daily volume of 219,127 shares. The stock had previously closed at $2.59.

Analyst Upgrades and Downgrades

TARA has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $23.00 price target on shares of Protara Therapeutics in a report on Thursday, August 8th. Oppenheimer cut their price objective on Protara Therapeutics from $30.00 to $25.00 and set an “outperform” rating for the company in a research report on Monday, August 12th.

Protara Therapeutics Stock Up 3.7 %

The company has a market capitalization of $52.40 million, a price-to-earnings ratio of -0.79 and a beta of 1.77. The stock’s 50-day simple moving average is $1.95 and its two-hundred day simple moving average is $2.31.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.82) by $0.37. On average, sell-side analysts forecast that Protara Therapeutics, Inc. will post -2.96 EPS for the current year.

Insiders Place Their Bets

In related news, major shareholder Opaleye Management Inc. sold 36,492 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $1.89, for a total value of $68,969.88. Following the completion of the transaction, the insider now directly owns 54,600 shares of the company’s stock, valued at approximately $103,194. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.50% of the stock is owned by company insiders.

Institutional Trading of Protara Therapeutics

Several large investors have recently bought and sold shares of the business. Oppenheimer & Co. Inc. acquired a new stake in shares of Protara Therapeutics in the 1st quarter worth $40,000. Ikarian Capital LLC increased its position in Protara Therapeutics by 7.4% during the first quarter. Ikarian Capital LLC now owns 202,701 shares of the company’s stock worth $813,000 after purchasing an additional 14,037 shares during the last quarter. Renaissance Technologies LLC increased its position in Protara Therapeutics by 77.8% during the second quarter. Renaissance Technologies LLC now owns 150,400 shares of the company’s stock worth $313,000 after purchasing an additional 65,800 shares during the last quarter. Marshall Wace LLP purchased a new position in Protara Therapeutics during the second quarter worth about $161,000. Finally, CVI Holdings LLC acquired a new stake in shares of Protara Therapeutics during the 2nd quarter worth approximately $630,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.